Which Dates Could Move Bristol Myers Squibb Stock Most?

BMYYTD+15.3%SPYYTD+7.9%XLVYTD+18.5%
Analyze BMY →

Today’s big story: Could Anthropic Stock Fall 25%?

Bristol Myers Squibb (BMY) stock has returned 32.9% over the past year, against 11.0% for the S&P 500. It lost 8.1% over the past three months, while the index lost 3.9%. Management has already said that Eliquis, its best-selling drug, will lose sales in Europe in fiscal Q4 2026. Below are the events most likely to move Bristol Myers Squibb stock over the next six months. They are listed soonest first.

What to watch When Which way it cuts
Eliquis loses its market exclusivity in Europe fiscal Q4 2026 (October to December 2026) Against the stock
Phase 3 data for Milvexian in preventing repeat strokes and for Sotyktu in lupus before the end of 2026 Either way
Fiscal Q4 2026 results report February 2027 Either way
Milvexian Phase 3 results in atrial fibrillation first quarter of 2027 Either way
Cobenfy trial results in Alzheimer’s disease psychosis, then bipolar I disorder early 2027 Either way
FDA decision date for Mezigdomide May 13, 2027 Either way
Image from Pixabay

Eliquis Sales In Europe

Eliquis loses its market exclusivity in Europe. Management expects this to weigh on the drug’s sales in fiscal Q4 2026. Growth in the U.S. should make up part of the gap. Eliquis is the company’s biggest drug, with $14.4 billion of sales in 2025. Management expects Eliquis revenue to step down by $1.5 billion to $2 billion in 2027.

Bristol Myers Squibb expects Eliquis sales to fall $1.5 billion to $2 billion in 2027, or 3% to 4% of its 2026 revenue guide. If this stock is a large share of your savings, you are counting on its other drugs to fill that hole. When the market has fallen, the Trefis High Quality (HQ) Portfolio has lost about 81 cents for every $1 its benchmark lost, on average. See the HQ record.

For now, the drug is still growing. In fiscal Q3 2026, Eliquis gains more than made up for generic losses on the company’s other older drugs. That same drug is the one management expects to shrink in 2027.

Milvexian Trial Results

Bristol Myers Squibb expects Phase 3 data for Milvexian in preventing repeat strokes before the end of 2026. Results for Milvexian in atrial fibrillation will follow in the first quarter of 2027.

Management has named its growth portfolio as its first priority going into 2027. This group of drugs brought in $7.7 billion in fiscal Q3 2026, up 12% from a year earlier. Management said it looks forward to adding drugs from its Phase 3 trials to its portfolio in 2027. If the Milvexian trials succeed, Bristol Myers Squibb would have one more new drug to set against the Eliquis decline. A miss would put more of that job on the drugs already on sale.

Bristol Myers Squibb’s February 2027 Report

Bristol Myers Squibb is expected to report its fiscal Q4 2026 results in February 2027. In October, management raised its 2026 revenue guide to $50.0 billion at the midpoint. Its July guide was $49.5 billion. Its guide for adjusted earnings per share went down, to $6.45 a share at the midpoint from its July guide of $6.88. Management said that came from charges for drug projects it bought, net of licensing income. Without them, the midpoint would have risen by about $0.15 a share.

Could You Sit Through Another Bristol Myers Squibb Fall?

Holding through these dates means being ready for a fall like the stock’s worst one of the past year. From September 3 to October 13, 2026, the share price fell 16.8% in 27 trading sessions. If a drop that deep would push you to sell, your holding is larger than you can sit through. You may find the risk easier to hold if growth portfolio sales keep rising as Eliquis sales shrink. The February 2027 report will show how far Eliquis sales in Europe fell in fiscal Q4 2026.

If this one stock already holds a big share of your savings, plan how you would get out now. Do it before these dates arrive, not after one of them.

Too Much Riding On One Stock?

If Bristol Myers Squibb is a big part of your wealth, so are its risk and its tax bill. What’s your exit plan? Our partner advisory firm offers a free 30-minute strategy review covering a floor under losses and a lower-tax way out.

Map My Exit Options

Spot an error or want more like this? Tell us in 10 seconds.